Framingham Heart Study Gutted

The iconic Framingham Heart Study, the longest-running cardiovascular study in the country, has been hit with a $4 million budget cut.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, HEIKENWAELDER HUGOThe 65-year-old Framingham Heart Study, which has studied the causes and effects of cardiovascular disease, is faced with $4 million in budget cuts due to sequestration. The cuts mean 19 of the 90 study staff members will lose their jobs, the Huffington Post reported. In addition, the cuts could mean that the next round of testing, to be conducted over the next two to three years, could be threatened.

“You’re going to lose a major investment that we’ve been making over the last 65 years,” Karen Antman, dean of Boston University School of Medicine, which co-runs the Framingham Heart Study, told the Huffington Post. “This is an iconic trial that has more than proven its value from a public health point of view.”

In 1948, the Framingham study began with funding from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Over the years, the cohort study has recruited more than 15,000 residents of Framingham, Mass., across three generations to help identify risk factors for diabetes, hypertension, hyperlipidemia, and other cardiovascular diseases. The Framingham study receives around $21 million in funding from the NIH annually, about ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Chris Palmer

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio